
“I think it’s really important that people keep signing up to these type of trials to push research forward.”
This trial was for people with an uncommon type of renal cell cancer called non clear cell kidney cancer. Cancer Research UK supported this trial.
When this trial was done, there wasn’t a standard treatment for non clear cell kidney cancer that had spread to another part of the body. Early research showed that either sunitinib or everolimus might be a useful treatment.
Sunitinib and everolimus are both types of called cancer growth blockers. They block signals that cancer cells use to divide and grow but work in slightly different ways.
In this trial, researchers wanted to find out which treatment worked better for this group of people.
The aims of this trial were to
The trial team found that sunitinb worked better than everolimus for people with non clear cell renal cell cancer.
This was a randomised trial. 108 people took part. They were put into 1 of 2 treatment groups.
The researchers looked at the average length of time people lived without signs of their cancer getting worse. This is called progression free survival. On average it was
The more serious side effects of both drugs included
These were more common in the people who had had sunitinib.
The trial team concluded that sunitinib improved progression free survival in this group of patients.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists () and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Andy Armstrong
Professor Rob Jones
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUKE/10/015.
Freephone 0808 800 4040
“I think it’s really important that people keep signing up to these type of trials to push research forward.”